A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients With Advanced AML or High Risk Myelodysplastic Syndrome
Latest Information Update: 04 Aug 2022
At a glance
- Drugs I-131-Apamistamab (Primary) ; Ciclosporin; Ciclosporin; Fludarabine; Mycophenolate mofetil
- Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
- Focus Adverse reactions
- 07 Jul 2022 Status changed from completed to discontinued.
- 20 Jul 2016 Status changed from active, no longer recruiting to completed, as reported by Actinium Pharmaceuticals media release.
- 16 Jun 2014 Planned primary completion date changed from 1 July 2015 to 1 Aug 2014 as reported by ClinicalTrials.gov record.